title: Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis.
abstract: OBJECTIVE
  Standard therapy for soft-tissue sarcomas remains complete resection. For primary radiotherapy local control rates of 30-45% have been reported. We analyzed retrospectively 11 cases of radiochemotherapy with single-agent ifosfamide in patients with macroscopic soft-tissue sarcomas.
  
  
  METHODS
  The patients were treated in irresectable high risk situations. Radiation therapy was performed with median 60 Gy. During the first and fifth week the concomitant chemotherapy with ifosfamide was added. Two patients received trimodal therapy with additional regional hyperthermia.
  
  
  RESULTS
  The therapy was completed in 73% of the patients. Average local control time was 91 months, median disease-free-survival/overall-survival was 8/26 months. Five-year rates for local control/disease free survival/overall survival were 70%/34%/34%. The limited prognosis is mainly caused by systemic treatment failure.
  
  
  CONCLUSIONS
  The data strongly suggest a better outcome of radiochemotherapy with ifosfamide compared to radiotherapy alone and radiotherapy in combination with other radiosensitizers.
authors.affiliation: Eberhard-Karls-University Tuebingen, Department of Radiooncology, Tuebingen, Germany. franziska.eckert@med.uni-tuebingen.de
authors.forename: Franziska
authors.initials: F
authors.lastname: Eckert
authors.forename: Christiane
authors.initials: C
authors.lastname: Matuschek
authors.forename: Arndt-Christian
authors.initials: AC
authors.lastname: Mueller
authors.forename: Martin
authors.initials: M
authors.lastname: Weinmann
authors.forename: Joerg T
authors.initials: JT
authors.lastname: Hartmann
authors.forename: Claus
authors.initials: C
authors.lastname: Belka
authors.forename: Wilfried
authors.initials: W
authors.lastname: Budach
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D011838:Radiation-Sensitizing Agents; D007069:Ifosfamide